XBIO Stock Overview
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xenetic Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.14 |
| 52 Week High | US$5.97 |
| 52 Week Low | US$2.55 |
| Beta | 2.67 |
| 1 Month Change | -2.59% |
| 3 Month Change | 19.14% |
| 1 Year Change | -13.75% |
| 3 Year Change | -79.30% |
| 5 Year Change | -97.61% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Shareholder Returns
| XBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | -4.7% | -3.7% |
| 1Y | -13.8% | -2.7% | 20.2% |
Return vs Industry: XBIO underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: XBIO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| XBIO volatility | |
|---|---|
| XBIO Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: XBIO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Jeff Eisenberg | www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Xenetic Biosciences, Inc. Fundamentals Summary
| XBIO fundamental statistics | |
|---|---|
| Market cap | US$6.38m |
| Earnings (TTM) | -US$4.13m |
| Revenue (TTM) | US$2.54m |
2.5x
P/S Ratio-1.5x
P/E RatioIs XBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBIO income statement (TTM) | |
|---|---|
| Revenue | US$2.54m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.54m |
| Other Expenses | US$6.67m |
| Earnings | -US$4.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 100.00% |
| Net Profit Margin | -162.78% |
| Debt/Equity Ratio | 0% |
How did XBIO perform over the long term?
See historical performance and comparison